In silico study of thymohydroquinone interaction with blood-brain barrier disrupting proteins.

Fahad Hassan Shah Saad SalmanJawaria IdreesFariha IdreesMuhammad Yasir Akbar

Published in: Future science OA (2020)

Further pharmacokinetic analysis revealed that thymohydroquinone is BBB and central nervous system (CNS) permeant with high acute toxicity and could be a candidate drug for the treatment of these neurological conditions.

Keyphrases

blood brain barrier
cerebral ischemia
liver failure
drug induced
oxidative stress
molecular docking
respiratory failure
emergency department
intensive care unit
cerebrospinal fluid
combination therapy
brain injury
adverse drug
acute respiratory distress syndrome